In 2026, the State Administration for Market Regulation (SAMR) initiated the accelerated conversion of over 1,800 national standards—including key recommended standards for medical imaging equipment and gamma irradiation/ethylene oxide (EO) sterilization systems—into mandatory national standards. The first batch of these conversions launched in Q1 2026. This development directly affects enterprises involved in the export of medical devices to regulated markets such as the EU and the U.S., particularly those engaged in CE or FDA conformity assessment pathways.

Event Overview

In 2026, SAMR launched a standardization initiative covering more than 1,800 standard revisions and new developments. Among them, recommended national standards for medical imaging devices and γ-irradiation/EO sterilization systems are being prioritized for conversion into mandatory national standards. The conversion focuses on clauses related to safety, electromagnetic compatibility (EMC), biocompatibility, and sterilization validation—areas highly scrutinized by overseas importers and regulatory authorities. The first group of projects began implementation in Q1 2026.

Industries Affected by Segment

Medical Device Exporters (Direct Trade Enterprises)

These enterprises face heightened compliance expectations from overseas buyers who assess supplier stability and regulatory alignment based on Chinese mandatory standards. Impact manifests in extended pre-market review timelines, increased documentation requirements for CE/FDA submissions, and potential delays in synchronization between Chinese and foreign certification processes.

Manufacturers of Imaging & Sterilization Equipment (Processing & Manufacturing Enterprises)

Manufacturers must align product design, testing protocols, and quality management systems with newly mandated requirements. Impact includes revised type-testing scope (e.g., expanded EMC test frequencies), updated biological evaluation strategies, and stricter validation evidence for sterilization cycles—especially for EO and gamma-based systems.

Suppliers of Critical Components (Raw Material & Subsystem Procurement Enterprises)

Suppliers providing materials used in imaging detectors, shielding enclosures, or sterilization chamber linings may face downstream demand shifts. Impact centers on traceability documentation, material-specific biocompatibility data, and compliance declarations aligned with the newly mandatory clauses—notably those referencing ISO 10993, IEC 62304, and ISO 11135/11137.

Regulatory & Certification Service Providers (Supply Chain Support Enterprises)

Third-party labs, notified bodies, and consulting firms supporting Chinese exporters must adjust service offerings to reflect the revised scope of mandatory conformity assessments. Impact includes updated test protocols, revalidation of existing test reports against new mandatory thresholds, and increased demand for bilingual technical documentation review services.

What Enterprises and Practitioners Should Focus On and How to Respond

Monitor Official Updates from SAMR and Standardization Administration of China (SAC)

Track published draft mandatory standards, official implementation timelines, and transitional arrangements. Conversion does not automatically trigger immediate enforcement—some standards may include grace periods or phased rollouts. Rely only on SAC’s official announcements (www.sac.gov.cn) and SAMR’s public notices, not unofficial interpretations.

Identify Priority Product Categories and Export Markets Most Impacted

Focus initial review efforts on products falling under GB 9706.1 (medical electrical equipment safety), GB/T 18279 (EO sterilization), and GB/T 18280 (gamma sterilization), especially where CE or FDA submissions are pending or underway. Prioritize markets where mutual recognition or audit coordination with Chinese regulators is limited—e.g., certain ASEAN or Latin American jurisdictions relying on Chinese conformity evidence.

Distinguish Between Policy Signal and Operational Implementation

The Q1 2026 launch signals intent and priority—not full legal effect. A standard’s conversion into mandatory status becomes effective only upon formal publication in the national standard catalogue and inclusion in the list of enforceable mandatory standards (GB, not GB/T). Until then, referenced clauses remain advisory unless otherwise specified in contractual or regulatory commitments.

Update Internal Documentation, Supplier Agreements, and Test Planning Now

Review current technical files and update risk management documentation to reflect anticipated mandatory requirements. Revise procurement contracts to require biocompatibility or sterilization validation data from component suppliers. Adjust 2026–2027 test planning calendars to allocate capacity for additional EMC or cycle validation tests—particularly where legacy test reports lack coverage of newly emphasized parameters.

Editorial Perspective / Industry Observation

Observably, this initiative reflects a structural shift in China’s medical device regulatory posture: from harmonizing with international norms to consolidating domestic technical baselines as enforceable requirements. Analysis shows that the acceleration targets high-risk, export-sensitive categories—not broad-based standardization. It is best understood not as an immediate compliance deadline, but as a signal of tightening regulatory convergence pressure on manufacturers whose global market access depends on synchronized conformity pathways. From an industry perspective, the pace of conversion—and its linkage to inspection enforcement—will determine whether it functions primarily as a preparatory benchmark or a binding operational constraint. Continuous monitoring of SAC’s published mandatory standard lists remains essential.

This development underscores how domestic standardization policy increasingly shapes cross-border regulatory interoperability. Rather than representing a standalone compliance event, it signals a longer-term recalibration of technical expectations for Chinese medical device exporters—where alignment with mandatory GBs may soon serve as a de facto prerequisite for third-country certification acceptance. Currently, it is more accurate to interpret this as a directional policy signal with phased implementation implications, rather than a completed regulatory change.

Information Sources:
— State Administration for Market Regulation (SAMR) official notice, Q1 2026
— Standardization Administration of China (SAC) public database: www.sac.gov.cn
Note: Specific standard numbers, exact enforcement dates beyond Q1 2026 rollout, and transitional provisions remain subject to ongoing official publication and require continuous observation.